Teva completes acquisition of Theramex from Merck Serono
This article was originally published in Scrip
Teva Pharmaceutical has completed the acquisition of Theramex, Merck KGaA's European-based women's health business, just over two months after the €265 million deal was announced at the end of October 2010.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.